Page 46 - Nuclear Export News Today : Breaking News, Live Updates & Top Stories | Vimarsana

(2) DJ EQS-News: Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy EQS-News / 21/12/2020 / 15:21 UTC+8 Antengene Announces its U.S. Partner, Karyopharm Therapeutics Inc., has received FDA Approval of XPOVIO(R) (Selinexor) as a Treatment for Patients with Multiple Myeloma After At Least One Prior Therapy --Oral XPOVIO(R) Approval as Combination Therapy in Patients with Multiple Myeloma After At Least One Prio...

Share this article Share this article SHANGHAI and HONG KONG, Dec.18, 2020 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application for ATG-010 (selinexor), an oral Selective Inhibitor of Nuclear Export compound, in combination with bortezomib and dexamethasone for...

Published: Dec 15, 2020   NEWTON, Mass., Dec. 15, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced the appointment of Michael Mano as Senior Vice President, General Counsel.  Mr. Mano brings over 15 years of legal experience and previously served as Counsel, Business Development at Biogen Inc. "Michael's depth of legal experience, particularly in the public life science sector supporting partnerships, intellectual property licensing, corporate governance, and financing efforts, ...

/PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing...

Karyopharm Announces National Comprehensive Cancer Network® Adds Three XPOVIO® (selinexor) Treatment Regimens to Its Clinical Practice Guidelines in Oncology for Multiple Myeloma News provided by Share this article Share this article NEWTON, Mass., Dec. 11, 2020 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the National Comprehensive Cancer Network® (NCCN) added three different XPOVIO® (selinexor) combination regimens to its Clinical Practice Guidelines in Oncology (NCCN Guidel...